<DOC>
	<DOCNO>NCT01650285</DOCNO>
	<brief_summary>There high relapse rate patient undergone prostatectomy pathologic extracapsular prostate extension , positive surgical margin seminal vesicle involvement ( pathologic stage 3 disease ) . While adjuvant radiation improve progression-free overall survival , approximately half patient develop recurrence . Similarly , radiation therapy become standard salvage therapy patient rise PSA &gt; 0.1 - &lt; 2.0 ng/mL . In common solid tumor NSCLC , head neck cancer upper gastrointestinal cancer , addition chemotherapy radiation improve survival . It hypothesize addition radiosensitizing chemotherapy standard adjuvant radiation improve survival patient stage 3 prostate cancer prostatectomy patient rise PSA &lt; 2.0 ng.mL without detectable disease . Taxanes powerful radiation enhancer since synchronize tumor cell G2/M radiosensitive phase cell cycle.17,18 Cabazitaxel active taxane treatment prostate cancer . Therefore , propose phase I study establish optimal dose cabazitaxel adjuvant radiation stage 3 prostate cancer prostatectomy ( PSA undetectable - &lt; 2.0 ng/mL ) . patient persistent rise PSA post prostatectomy ( PSA &gt; 0.1 - &lt; 2.0 ng/mL ) .</brief_summary>
	<brief_title>Cabazitaxel Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation ( &gt; 0.1- &lt; 2.0 ng/mL )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Conditions Patient Eligibility Each patient must meet follow inclusion criterion enrol study : Radical prostatectomy adenocarcinoma prostate least one following : Extracapsular tumor extension , Positive surgical margin , Seminal vesicle invasion Regional lymph node positive ( N1 ) Postprostatectomy PSA &gt; 0.1 &lt; 2.0 ng/mL least 6 week prostatectomy within 30 day registration patient T2 T3 disease prostatectomy . No distant metastasis . No prior pelvic prostate radiation chemotherapy prostate cancer . ECOG performance status 01 . Age &gt; 18 . Required entry laboratory parameter within 14 day study entry : Granulocytes ≥ 1500 cells/mm3 ; platelet count ≥100,000 cells/mm3 , Creatinine ≤ 1.5X upper limit normal ( creatinine clearance 1.01.5x ULN , creatinine clearance calculate accord Chronic Kidney Disease Epidemiology Group formula patient creatinine clearance &lt; 60 ml/min exclude ) ,19 .Hgb &gt; 9.0 g/dl , total bilirubin ≤ 1x ULN , AST ALT ≤ 2.5 x ULN . Life expectancy least 1 year . Must uncontrolled severe , intercurrent illness . No concurrent anticancer therapy . Men childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Signed studyspecific consent form prior study entry . Conditions Patient Ineligibility Patients meeting follow exclusion criterion enrol study : Evidence distant metastasis ( M1 ) . Equivocal bone scan allow plain film negative metastasis . Major medical psychiatric illness , investigator 's opinion , would prevent completion treatment would interfere followup . Prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free minimum 2 year ( For example , carcinoma situ oral cavity bladder permissible ) . History severe hypersensitivity ( &gt; grade 3 ) reaction Cabazitaxel drug formulate polysorbate 80 . History severe hypersensitivity ( &gt; grade 3 ) docetaxel . Any uncontrolled severe , intercurrent illness ( include uncontrolled diabetes ) At least 4 week since major surgery . Patients concurrent anticancer therapy . PSA &gt; 2ng/ml Concurrent plan treatment strong inhibitor inducer cytochrome p450 3A4/5 ( oneweek wash period necessary patient already treatment ( see appendix H I ) Androgen deprivation therapy start prior prostatectomy &gt; 6 month duration ; Neoadjuvant chemotherapy prior prostatectomy ; Prior cryosurgery brachytherapy prostate ; prostatectomy primary treatment salvage procedure ; Prior pelvic radiotherapy ;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Radical prostatectomy</keyword>
</DOC>